AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 38216290 — intervention group
Group type: EXPERIMENTAL
Intervention: RAID components (pain)
Number of subjects: 248
Study 38216290 — intervention group
Group type: EXPERIMENTAL
Intervention: RAID components (sleep)
Number of subjects: 248
Study 38216296 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intrafemoral thrombolysis (urokinase injection for 7 days)
Number of subjects: 195
Study 38216319 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdraw GC+IM (group 1)
Number of subjects: 146
Study 38216319 — intervention group
Group type: COMPARATOR
Intervention: Withdraw GC but maintain IM (group 2)
Number of subjects: 146
Study 38216319 — intervention group
Group type: COMPARATOR
Intervention: Maintain GC+IM (group 3)
Number of subjects: 146
Study 38216351 — intervention group
Group type: EXPERIMENTAL
Intervention: CSF-1 (0.4% pilocarpine hydrochloride)
Number of subjects: 613
Study 38216351 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 613
Study 38216389 — intervention group
Group type: EXPERIMENTAL
Intervention: DIAGNOcam
Number of subjects: 60
Study 38216389 — intervention group
Group type: COMPARATOR
Intervention: Bitewing (BW) radiographs
Number of subjects: 60
Study 38216389 — intervention group
Group type: COMPARATOR
Intervention: Temporary teeth separation
Number of subjects: 60
Study 38216511 — intervention group
Group type: EXPERIMENTAL
Intervention: Flecainide (150 mg per day in a single sustained-release dose) for 6 months
Number of subjects: 186
Study 38216511 — intervention group
Group type: EXPERIMENTAL
Intervention: Flecainide (150 mg per day in a single sustained-release dose) for 3 months
Number of subjects: 186
Study 38216511 — intervention group
Group type: COMPARATOR
Intervention: No additional treatment (standard of care) for 6 months
Number of subjects: 186
Study 38216543 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital platform + Community Health Worker (CHW) pairing + Usual care
Number of subjects: 50
Study 38216543 — intervention group
Group type: COMPARATOR
Intervention: CHW pairing + Usual care
Number of subjects: 50
Study 38216543 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital platform + CHW pairing + Usual care
Number of subjects: 50
Study 38216554 — intervention group
Group type: EXPERIMENTAL
Intervention: Carcinoembryonic antigen-expressing oncolytic measles virus derivative (MV-CEA) administered at the resection cavity (Group A)
Number of subjects: 22
Study 38216554 — intervention group
Group type: EXPERIMENTAL
Intervention: Carcinoembryonic antigen-expressing oncolytic measles virus derivative (MV-CEA) administered intratumorally on day 1, followed by a second dose in the resection cavity on day 5 (Group B)
Number of subjects: 22
Study 38216566 — intervention group
Group type: EXPERIMENTAL
Intervention: If/when-then planning prompts (standard letter)
Number of subjects: 541
Study 38216566 — intervention group
Group type: COMPARATOR
Intervention: Comparator version of the letter (control)
Number of subjects: 541
Study 38216647 — intervention group
Group type: EXPERIMENTAL
Intervention: Normocaloric MUFAs-rich diet (15-20% TEE)
Number of subjects: 32
Study 38216728 — intervention group
Group type: EXPERIMENTAL
Intervention: Belimumab
Number of subjects: 3225
Study 38216728 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3225
Study 38216766 — intervention group
Group type: EXPERIMENTAL
Intervention: CAR T-EGFRvIII cells + pembrolizumab (anti-PD1)
Number of subjects: 0
Study 38216766 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 38216784 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender-affirming hormone therapy for trans women
Number of subjects: 70
Study 38216784 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender-affirming hormone therapy for trans men
Number of subjects: 70
Study 38216784 — intervention group
Group type: COMPARATOR
Intervention: Cisgender women
Number of subjects: 70
Study 38216784 — intervention group
Group type: COMPARATOR
Intervention: Cisgender men
Number of subjects: 70
Study 38216803 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser acupuncture
Number of subjects: 84
Study 38216831 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg daily
Number of subjects: 8
Study 38216905 — intervention group
Group type: EXPERIMENTAL
Intervention: Class 1 (Positive class, n=169, 39%)
Number of subjects: 435
Study 38216905 — intervention group
Group type: EXPERIMENTAL
Intervention: Class 2 (Fearful class, n=31, 7%)
Number of subjects: 435
Study 38216905 — intervention group
Group type: EXPERIMENTAL
Intervention: Class 3 (Distressed class, n=33, 8%)
Number of subjects: 435
Study 38216905 — intervention group
Group type: EXPERIMENTAL
Intervention: Class 4 (Hopeful class, n=202, 46%)
Number of subjects: 435
Study 38216967 — intervention group
Group type: EXPERIMENTAL
Intervention: STRIDE program with foundational support
Number of subjects: 32
Study 38216967 — intervention group
Group type: EXPERIMENTAL
Intervention: STRIDE program with enhanced support
Number of subjects: 32
Study 38216967 — intervention group
Group type: EXPERIMENTAL
Intervention: STRIDE program
Number of subjects: 32
Study 38216967 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-level effectiveness outcomes
Number of subjects: 32
Study 38216971 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile application (ESTOI) for asthma management with exhaustive follow-up
Number of subjects: 108
Study 38216971 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile application (ESTOI) for asthma management
Number of subjects: 108
Study 38216985 — intervention group
Group type: COMPARATOR
Intervention: Low blood pressure target (63 mmHg)
Number of subjects: 789
Study 38216985 — intervention group
Group type: EXPERIMENTAL
Intervention: High blood pressure target (77 mmHg)
Number of subjects: 789
Study 38216985 — intervention group
Group type: COMPARATOR
Intervention: Restrictive oxygenation target (9-10 kPa)
Number of subjects: 789
Study 38216985 — intervention group
Group type: EXPERIMENTAL
Intervention: Liberal oxygenation target (13-14 kPa)
Number of subjects: 789
Study 38216985 — intervention group
Group type: COMPARATOR
Intervention: Device-based fever prevention for 36 hours
Number of subjects: 789
Study 38216985 — intervention group
Group type: EXPERIMENTAL
Intervention: Device-based fever prevention for 72 hours
Number of subjects: 789
Study 38217032 — intervention group
Group type: EXPERIMENTAL
Intervention: Upfront, early radiotherapy to ≤ 5 high-risk spine lesions plus standard-of-care systemic therapy (20-30 Gy of radiation in 2-10 fractions)
Number of subjects: 74
Study 38217032 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care systemic therapy
Number of subjects: 74
Study 38217039 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine osmolality > 760 mosmol/kg or urine creatinine > 13 mmol/L
Number of subjects: 20
Study 38217039 — intervention group
Group type: EXPERIMENTAL
Intervention: Days with urine output < 1 L
Number of subjects: 20
Study 38217039 — intervention group
Group type: EXPERIMENTAL
Intervention: Age-corrected biomarker cutoffs
Number of subjects: 20
Study 38217343 — intervention group
Group type: EXPERIMENTAL
Intervention: Subendocardial viability ratio (SEVR) estimated non-invasively by analyzing the carotid pressure waveform recorded by applanation arterial tonometry.
Number of subjects: 828
Study 38217361 — intervention group
Group type: EXPERIMENTAL
Intervention: LEO cohort study participants
Number of subjects: 7735
Study 38217402 — intervention group
Group type: EXPERIMENTAL
Intervention: Vascular occlusion test (VOT) using near-infrared spectroscopy
Number of subjects: 120
Study 38217481 — intervention group
Group type: EXPERIMENTAL
Intervention: CASA score (0-6) based on cheeks appearance scored for volume (0-3) and flaccidity (0-3) by 3 blinded evaluators.
Number of subjects: 248
Study 38217640 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevision hip stem
Number of subjects: 44
Study 38217757 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouthwash with amine + zinc lactate + fluoride system
Number of subjects: 0
Study 38217757 — intervention group
Group type: COMPARATOR
Intervention: Negative control mouthwash
Number of subjects: 0
Study 38217877 — intervention group
Group type: EXPERIMENTAL
Intervention: Very old stroke patients (80 years or older)
Number of subjects: 463
Study 38217929 — intervention group
Group type: EXPERIMENTAL
Intervention: Delays in childbirth care
Number of subjects: 16
Study 38217929 — intervention group
Group type: EXPERIMENTAL
Intervention: High patient-to-provider ratio during antenatal care
Number of subjects: 16
Study 38217929 — intervention group
Group type: EXPERIMENTAL
Intervention: Delays in care decision-making and patient management
Number of subjects: 16
Study 38217929 — intervention group
Group type: EXPERIMENTAL
Intervention: Need for comprehensive childbirth interventions
Number of subjects: 16
Study 38217929 — intervention group
Group type: EXPERIMENTAL
Intervention: Need for context-specific guidelines
Number of subjects: 16
Study 38218013 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise (AE)
Number of subjects: 90
Study 38218013 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi Chuan (TCC)
Number of subjects: 90
Study 38218013 — intervention group
Group type: COMPARATOR
Intervention: Wait-list Control (WLC)
Number of subjects: 90
Study 38218157 — intervention group
Group type: EXPERIMENTAL
Intervention: iMRI
Number of subjects: 321
Study 38218157 — intervention group
Group type: COMPARATOR
Intervention: Control (conventional neuronavigation)
Number of subjects: 321
Study 38218194 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexinidazole 600 mg once daily for 10 days (6.0 g total dose)
Number of subjects: 45
Study 38218194 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexinidazole 1200 mg daily for 3 days (3.6 g total)
Number of subjects: 45
Study 38218194 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexinidazole 600 mg daily for 3 days followed by 1200 mg daily for 4 days (6.6 g total)
Number of subjects: 45
Study 38218194 — intervention group
Group type: COMPARATOR
Intervention: Historical placebo control group
Number of subjects: 45
Study 38218195 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg/day for 60 days (low dose group)
Number of subjects: 234
Study 38218195 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg/day for 15 days (short treatment group)
Number of subjects: 234
Study 38218195 — intervention group
Group type: COMPARATOR
Intervention: 300 mg/day for 60 days (control group)
Number of subjects: 234
Study 38218392 — intervention group
Group type: EXPERIMENTAL
Intervention: TAPSE/PASP ratio
Number of subjects: 422
Study 38218392 — intervention group
Group type: EXPERIMENTAL
Intervention: TAPSE/PASP ≤0.33
Number of subjects: 422
Study 38218784 — intervention group
Group type: EXPERIMENTAL
Intervention: Nature-based social intervention 'Friends in Nature'
Number of subjects: 316
Study 38218784 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 316
Study 38218843 — intervention group
Group type: EXPERIMENTAL
Intervention: History of diabetic foot (including ulcer/gangrene, amputation, and lower limb revascularization)
Number of subjects: 15773
Study 38218843 — intervention group
Group type: EXPERIMENTAL
Intervention: Amputation
Number of subjects: 15773
Study 38218843 — intervention group
Group type: EXPERIMENTAL
Intervention: Revascularization alone
Number of subjects: 15773
Study 38218899 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based information platform (www.ich-bin-alles.de/eltern)
Number of subjects: 33
Study 38218919 — intervention group
Group type: EXPERIMENTAL
Intervention: YAG laser vitreolysis (early treatment group)
Number of subjects: 70
Study 38218919 — intervention group
Group type: COMPARATOR
Intervention: Sham laser treatment (early treatment group)
Number of subjects: 70
Study 38218919 — intervention group
Group type: EXPERIMENTAL
Intervention: YAG laser vitreolysis (delayed treatment group)
Number of subjects: 70
Study 38218919 — intervention group
Group type: COMPARATOR
Intervention: Sham laser treatment (delayed treatment group)
Number of subjects: 70
Study 38218919 — intervention group
Group type: EXPERIMENTAL
Intervention: YAG laser vitreolysis
Number of subjects: 70
Study 38218919 — intervention group
Group type: COMPARATOR
Intervention: Sham laser treatment
Number of subjects: 70
Study 38218924 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose quadruple antihypertensives (irbesartan 75 mg + metoprolol 23.75 mg + amlodipine 2.5 mg + indapamide 1.25 mg)
Number of subjects: 90
Study 38218924 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose dual antihypertensives (irbesartan 150 mg + amlodipine 5 mg)
Number of subjects: 90
Study 38218932 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS
Number of subjects: 88
Study 38218932 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 88
Study 38218936 — intervention group
Group type: EXPERIMENTAL
Intervention: telephone-delivered Common Elements Treatment Approach (t-CETA)
Number of subjects: 25
Study 38218979 — intervention group
Group type: EXPERIMENTAL
Intervention: VT1021 (11.8 mg/kg, RP2D)
Number of subjects: 38
Study 38219024 — intervention group
Group type: EXPERIMENTAL
Intervention: Nirsevimab
Number of subjects: 0
Study 38219024 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 38219041 — intervention group
Group type: EXPERIMENTAL
Intervention: Stable short sleep group (6-hour TIB)
Number of subjects: 52
Study 38219041 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable short sleep group (8-hour, 4-hour, 8-hour, 4-hour, 6-hour TIB)
Number of subjects: 52
Study 38219041 — intervention group
Group type: COMPARATOR
Intervention: Control group (8-hour TIB)
Number of subjects: 52
Study 38219041 — intervention group
Group type: EXPERIMENTAL
Intervention: Stable short sleep group
Number of subjects: 52
Study 38219041 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable short sleep group
Number of subjects: 52
Study 38219156 — intervention group
Group type: EXPERIMENTAL
Intervention: Positional distraction with stabilisation exercises (Group A)
Number of subjects: 100
Study 38219156 — intervention group
Group type: COMPARATOR
Intervention: Stabilisation exercises alone (Group B)
Number of subjects: 100
Study 38219157 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle energy techniques (Group A)
Number of subjects: 105
Study 38219157 — intervention group
Group type: EXPERIMENTAL
Intervention: Facet joint mobilisation (Group B)
Number of subjects: 105
Study 38219157 — intervention group
Group type: COMPARATOR
Intervention: Conventional physical therapy (Group C)
Number of subjects: 105
Study 38219179 — intervention group
Group type: EXPERIMENTAL
Intervention: Trunk stabilisation exercises
Number of subjects: 28
Study 38219179 — intervention group
Group type: COMPARATOR
Intervention: Trunk activation exercises
Number of subjects: 28
Study 38219767 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin alone
Number of subjects: 1950
Study 38219767 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin plus stent
Number of subjects: 1950
Study 38219773 — intervention group
Group type: EXPERIMENTAL
Intervention: Revealed group (cerebroplacental ratio known)
Number of subjects: 9492
Study 38219773 — intervention group
Group type: COMPARATOR
Intervention: Concealed group (cerebroplacental ratio unknown)
Number of subjects: 9492
Study 38219864 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative dietary fiber intake (assessed as area under the curve for energy-adjusted fiber intake from age 0-26 years)
Number of subjects: 357
Study 38219864 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative dietary fiber intake
Number of subjects: 357
Study 38220413 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin (three capsules of 500 mg of Curcuma longa extract, with 98.42 % total curcuminoids) for twelve weeks
Number of subjects: 48
Study 38220413 — intervention group
Group type: COMPARATOR
Intervention: Placebo (three capsules of 500 mg of starch) for twelve weeks
Number of subjects: 48
Study 38220592 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined aerobic and resistance exercise + cognitive training (CARE+CT)
Number of subjects: 72
Study 38220592 — intervention group
Group type: COMPARATOR
Intervention: Stretching exercise + cognitive training (SE+CT)
Number of subjects: 72
Study 38220592 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (CARE+CT and SE+CT)
Number of subjects: 72
Study 38221545 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative radiotherapy (IORT)
Number of subjects: 436
Study 38221601 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-Child Interaction Therapy-Emotion Development (PCIT-ED)
Number of subjects: 62
Study 38221601 — intervention group
Group type: COMPARATOR
Intervention: Online parenting education
Number of subjects: 62
Study 38221808 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg hydromorphone (Day 2)
Number of subjects: 100
Study 38221808 — intervention group
Group type: EXPERIMENTAL
Intervention: 0 mg, 2 mg and 8 mg hydromorphone (Days 3-5)
Number of subjects: 100
Study 38221808 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 100
Study 38222041 — intervention group
Group type: EXPERIMENTAL
Intervention: Emicizumab Prophylaxis
Number of subjects: 0
Study 38222040 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk scores for thromboprophylaxis
Number of subjects: 0
Study 38222057 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (ET) program within <2 years post-radiotherapy
Number of subjects: 0
Study 38222057 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (ET) program between 2 to 5 years post-radiotherapy
Number of subjects: 0
Study 38222057 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine post-radiotherapy care including ET program
Number of subjects: 0
Study 38222092 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Behavior group (HB) - Remote coaching on diet, moderate-intensity walking, and breathing exercises
Number of subjects: 44
Study 38222095 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardised limited echo protocol
Number of subjects: 0
Study 38222252 — intervention group
Group type: EXPERIMENTAL
Intervention: COOL-AF scores in APHRS
Number of subjects: 3628
Study 38222252 — intervention group
Group type: COMPARATOR
Intervention: CHA scores
Number of subjects: 3628
Study 38222256 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients without SMuRFs
Number of subjects: 10775
Study 38222256 — intervention group
Group type: COMPARATOR
Intervention: Patients with SMuRFs
Number of subjects: 10775
Study 38222312 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphodepletion therapy consisting of cyclophosphamide (30mg/kg) for 2 days followed by Fludarabine (25mg/m2) and TILs infusion.
Number of subjects: 2
Study 38222876 — intervention group
Group type: EXPERIMENTAL
Intervention: Islamic Trauma Healing (ITH) intervention, a 6-session manualized mosque-based, lay-led group intervention combining Islamic principles with exposure and cognitive restructuring for PTSD.
Number of subjects: 200
Study 38222876 — intervention group
Group type: COMPARATOR
Intervention: Delayed (waitlist; WL) ITH condition (control group).
Number of subjects: 200
Study 38222876 — intervention group
Group type: EXPERIMENTAL
Intervention: Islamic Trauma Healing (ITH) intervention.
Number of subjects: 200
Study 38223663 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetanic stimulus applied to the ulnar nerve
Number of subjects: 12
Study 38223663 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetanic stimulus applied to the medial side of the tibia
Number of subjects: 12
Study 38223663 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetanic stimulus applied to the thorax (T5 dermatome)
Number of subjects: 12
Study 38224135 — intervention group
Group type: COMPARATOR
Intervention: Testosterone replacement therapy (TRT)
Number of subjects: 11419
Study 38224415 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 94
Study 38224415 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 94
Study 38224478 — intervention group
Group type: EXPERIMENTAL
Intervention: OCH-NCNP1 (3.0 mg, orally administered once weekly for 24 weeks)
Number of subjects: 30
Study 38224478 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 30
Study 38224478 — intervention group
Group type: EXPERIMENTAL
Intervention: OCH-NCNP1
Number of subjects: 30
Study 38224564 — intervention group
Group type: EXPERIMENTAL
Intervention: Next-generation multi-target stool DNA (mt-sDNA) test
Number of subjects: 232
Study 38224591 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT-I)
Number of subjects: 126
Study 38224591 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone
Number of subjects: 126
Study 38224591 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study 38224663 — intervention group
Group type: EXPERIMENTAL
Intervention: Definitive chemoradiation with a dose of 50.4 Gy in 28 fractions and a concomitant boost of 62 Gy in 28 fractions to the primary target volume (CTV-/PTV-T)
Number of subjects: 108
Study 38224706 — intervention group
Group type: EXPERIMENTAL
Intervention: IPTp with dihydroartemisinin-piperaquine plus daily co-trimoxazole
Number of subjects: 666
Study 38224706 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus daily co-trimoxazole
Number of subjects: 666
Study 38224710 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily co-trimoxazole plus monthly dihydroartemisinin-piperaquine (3 tablets of 40 mg dihydroartemisinin and 320 mg piperaquine for 3 days)
Number of subjects: 904
Study 38224710 — intervention group
Group type: COMPARATOR
Intervention: Daily co-trimoxazole plus monthly placebo
Number of subjects: 904
Study 38224710 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily co-trimoxazole plus monthly dihydroartemisinin-piperaquine
Number of subjects: 904
Study 38224916 — intervention group
Group type: EXPERIMENTAL
Intervention: MR-guided stereotactic ablative radiotherapy (SABR) with fractionation schemes of 45-67.5 Gy in 3-8 fractions
Number of subjects: 121
Study 38224916 — intervention group
Group type: EXPERIMENTAL
Intervention: MR-guided stereotactic ablative radiotherapy (SABR)
Number of subjects: 121
Study 38225549 — intervention group
Group type: EXPERIMENTAL
Intervention: nabiximols in combination with TMZ
Number of subjects: 0
Study 38225549 — intervention group
Group type: COMPARATOR
Intervention: placebo in combination with TMZ
Number of subjects: 0
Study 38225551 — intervention group
Group type: EXPERIMENTAL
Intervention: One-year supervised physical activity program
Number of subjects: 236
Study 38225561 — intervention group
Group type: EXPERIMENTAL
Intervention: Strengthening the brain - a lifestyle intervention combining personal fitness, mental coaching, dietary advice, and cognitive training
Number of subjects: 270